Rafferty Asset Management
CRSP icon

Rafferty Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Rafferty Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.05M Sell
55,833
-34,503
-38% -$1.82M 0.01% 542
2026
Q1 		$4.3M Sell
90,336
-10,678
-11% -$563K 0.02% 440
2025
Q4 		$5.3M Sell
101,014
-53,281
-35% -$3.19M 0.02% 419
2025
Q3 		$10M Buy
154,295
+39,947
+35% +$2.29M 0.03% 286
2025
Q2 		$5.56M Sell
114,348
-31,684
-22% -$1.23M 0.02% 376
2025
Q1 		$4.97M Sell
146,032
-19,784
-12% -$839K 0.02% 373
2024
Q4 		$6.53M Sell
165,816
-48,278
-23% -$2.28M 0.02% 359
2024
Q3 		$10.1M Buy
214,094
+31,533
+17% +$1.6M 0.03% 283
2024
Q2 		$9.86M Buy
182,561
+58,987
+48% +$3.41M 0.04% 285
2024
Q1 		$8.42M Sell
123,574
-23,763
-16% -$1.7M 0.03% 335
2023
Q4 		$9.22M Sell
147,337
-42,050
-22% -$2.32M 0.04% 304
2023
Q3 		$8.6M Buy
189,387
+42,478
+29% +$2.19M 0.05% 262
2023
Q2 		$8.25M Sell
146,909
-10,537
-7% -$598K 0.05% 260
2023
Q1 		$7.12M Sell
157,446
-7,206
-4% -$350K 0.05% 288
2022
Q4 		$6.69M Buy
164,652
+61,206
+59% +$3.25M 0.06% 312
2022
Q3 		$6.76M Buy
103,446
+43,569
+73% +$3.16M 0.07% 233
2022
Q2 		$3.64M Buy
59,877
+34,015
+132% +$2M 0.03% 348
2022
Q1 		$1.62M Sell
25,862
-3,402
-12% -$214K 0.01% 674
2021
Q4 		$2.22M Buy
29,264
+727
+3% +$63.5K 0.01% 620
2021
Q3 		$3.19M Sell
28,537
-3,001
-10% -$377K 0.02% 442
2021
Q2 		$5.11M Buy
+31,538
New +$3.84M 0.03% 310

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rafferty Asset Management's CRSP Position: Q2 2026 in Review

Rafferty Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 38% in Q2 2026, selling an estimated $1.82M and leaving 55,833 shares worth $3.05M. The position accounts for 0.01% of the portfolio, ranked #542.

Rafferty Asset Management first reported a position in CRSP in Q2 2021 and has held it in 21 quarters since. The position peaked at $10.1M in Q3 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Rafferty Asset Management held 55,833 shares of CRISPR Therapeutics worth $3.05M as of Q2 2026.
  • Rafferty Asset Management sold 34,503 CRISPR Therapeutics shares in Q2 2026, an estimated $1.82M.
  • CRISPR Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #542 holding.
  • Rafferty Asset Management first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Rafferty Asset Management's CRISPR Therapeutics position peaked at $10.1M in Q3 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.